LH May 2022 230.000 call
| Previous close | 17.35 |
| Open | 17.15 |
| Bid | 16.00 |
| Ask | 20.70 |
| Strike | 230.00 |
| Expiry date | 2022-05-20 |
| Day's range | 17.15 - 17.35 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
- Zacks
LabCorp (LH) Introduces Latest Assay for Skin Cancer Patients
LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.
- Business Wire
Labcorp Launches New Test for People With Skin Cancer
BURLINGTON, N.C., May 18, 2022--Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company. The new test measures Lymphocyte-activation gene 3 (LAG-3) expression levels by immunohistochemistry (IHC) in tumor tissue. LAG-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. The test is available for use in both clinical trials and for the care and treatment of patien
- Business Wire
Labcorp Receives Emergency Use Authorization for First Non-Prescription At-Home Collection Kit for Combined COVID-19, Flu and RSV Detection
BURLINGTON, N.C., May 18, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced the receipt of Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV), a common but contagious respiratory virus often seen in children.
